Vigabatrin

Table of Contents

Overview ......................................................... 1
Coverage Policy Statement ............................ 1
FDA Indication Criteria ................................. 2
Other Uses with Supportive Evidence Criteria ... 2
Specific Additional Criteria ............................. 2
Preferred Product Requirement Criteria ........... 2
Conditions Not Covered ................................. 3
Background .................................................... 3
References ..................................................... 4

Related Coverage Resources

Multi-Source Brand Name Drugs
Quantity Limitations

INSTRUCTIONS FOR USE

The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer’s particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer’s benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer’s benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. In certain markets, delegated vendor guidelines may be used to support medical necessity and other coverage determinations.

Overview

This policy supports medical necessity review for vigabatrin (Sabril).

Coverage Policy Statement

Prior authorization is recommended for prescription benefit coverage of vigabatrin. Because of the specialized skills required for evaluation and diagnosis of patients treated with vigabatrin as well as the monitoring required for adverse events and long-term efficacy, initial approval requires vigabatrin to be prescribed by, or in consultation with, a physician who specializes in the condition being treated. All approvals are provided for the duration noted below.

Vigabatrin (Sabril) is medically necessary when the following are met:

1. Criteria associated with FDA Indications
2. Criteria associated with Other Uses with Supportive Evidence
3. **Specific Additional Criteria** [when part of Cigna managed drug list or plan requirements]

4. **Preferred Product Requirement Criteria** [when part of Cigna managed drug list or plan requirements]

When coverage is available and medically necessary, the dosage, frequency, duration of therapy, and site of care should be reasonable, clinically appropriate, and supported by evidence-based literature and adjusted based upon severity, alternative available treatments, and previous response to therapy.

Approval duration is 12 months unless otherwise stated.

**Note:** Receipt of sample product does not satisfy any criteria requirements for coverage.

**Documentation:** When documentation is required, the prescriber must provide written documentation supporting the trials of these other agents. Documentation may include, but is not limited to, chart notes, prescription claims records, and/or prescription receipts.

Refer to each criteria section below.

### FDA Indication Criteria

1. **Infantile Spasms.** Approve for 6 months if the individual meets the following criteria (A, B and C):
   - A) The individual is ≤ 2 years of age; AND
   - B) Vigabatrin is being used as monotherapy; AND
   - C) Vigabatrin is prescribed by, or in consultation with, a neurologist.

2. **Treatment-Refractory Complex Partial Seizures.** Approve for the duration noted below if the individual meets ONE of the following criteria (A or B):
   - A) **Initial Therapy:** Approve for 3 months if the individual meets the following criteria (i, ii, and iii):
     - i. The individual is ≥ 2 years of age; AND
     - ii. The individual has tried and/or is concomitantly receiving at least three other antiepileptic drugs; AND
     - iii. Vigabatrin is prescribed by, or in consultation with, a neurologist.

   - **Note:** Examples of antiepileptic drugs include valproic acid, gabapentin, phenytoin, carbamazepine, oxcarbazepine, lacosamide, levetiracetam, zonisamide, Fycompa, lamotrigine, topiramate, rufinamide, tiagabine, felbamate, Diacomit, and clobazam.

   - B) **Individual is Currently Receiving Vigabatrin:** Approve for 1 year if the individual is responding to therapy (e.g., reduced seizure severity, frequency, and/or duration) as determined by the health care professional.

### Other Uses with Supportive Evidence Criteria

NONE

### Specific Additional Criteria

NONE

### Preferred Product Requirement Criteria

Coverage varies across plans. Refer to the customer’s benefit plan document for coverage details. Where coverage requires the use of preferred products, the following criteria apply:

Approve for an individual when there is documentation of ONE of the following:
• The individual has had inadequate efficacy OR contraindication according to FDA label OR significant intolerance to ALL of covered alternatives according to the table below. OR

• The individual is not a candidate for ALL covered alternatives according to the table below due to being subject to a warning per the prescribing information (labeling), having a disease characteristic, individual clinical factor[s], or other attributes/conditions or is unable to administer and requires this dosage formulation.

### Employer Group Non-Covered Products and Preferred Covered Alternatives by Drug List:

<table>
<thead>
<tr>
<th>Non-Covered Product</th>
<th>Standard / Performance</th>
<th>Value / Advantage</th>
<th>Cigna Total Savings</th>
<th>Legacy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sabril (vigabatrin)</td>
<td>• Meets Multi-Source Brand Name Drugs Policy criteria*</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Documentation that individual has tried the bioequivalent generic product AND cannot take due to a formulation difference in the inactive ingredient(s) [for example, difference in dyes, fillers, preservatives] between the brand and the bioequivalent generic product which, per the prescribing physician, would result in a significant allergy or serious adverse reaction]

### Conditions Not Covered

1. Any other use is considered experimental, investigational, or unproven. Criteria will be updated as new published data are available.

### Background

#### Overview

Vigabatrin is indicated as adjunctive therapy for adults and pediatric patients ≥ 2 years of age with refractory complex partial seizures who have inadequately responded to several alternative treatments and for whom the potential benefits outweigh the risk of vision loss. Vigabatrin is not indicated as a first line agent for complex partial seizures. Vigabatrin is also indicated as monotherapy for pediatric patients with infantile spasms 1 month to 2 years of age for whom the potential benefits outweigh the potential risk of vision loss.

According to the vigabatrin prescribing information, use the lowest dosage and shortest exposure to vigabatrin consistent with clinical objectives. For infantile spasms, vigabatrin is titrated to a maximum dose of 150 mg/kg/day given in two divided doses (75 mg/kg twice daily). In patients with infantile spasms, vigabatrin should be withdrawn if a substantial clinical benefit is not observed within 2 to 4 weeks. If, in the clinical judgment of the prescriber, evidence of treatment failure becomes obvious earlier than 2 to 4 weeks, treatment should be discontinued at that time. In a controlled clinical study in patients with infantile spasms, vigabatrin was tapered by decreasing the daily dose at a rate of 25 mg/kg to 50 mg/kg every 3 to 4 days. For refractory complex partial seizures, vigabatrin is titrated to 3,000 mg/day (1,500 mg twice daily) for patients ≥ 17 years of age and to 2,000 mg/day (1,000 mg twice daily) for pediatric patients 10 years to 16 years of age. In patients with refractory complex partial seizures, vigabatrin should be withdrawn if a substantial clinical benefit is not observed within 3 months of initiating treatment. If, in the clinical judgment of the prescriber, evidence of treatment failure becomes obvious earlier than 3 months, treatment should be discontinued at that time. In a controlled study in pediatric patients with complex partial seizures, vigabatrin was tapered by decreasing the daily dose by one third every week for 3 weeks.

The incidence of infantile spasms ranges from 2 to 3.5 per 10,000 live births and most patients present between the ages of 3 months to 7 months; 90% of patients present in the first year of life. Onset after 18 months of age is rare, although onset up to 4 years of age has been reported. Infantile spasms are a catastrophic form of epilepsy in children and poor developmental outcome may result. The recommended duration therapy for Acthar is short-term (2 weeks of treatment followed by a gradual taper and discontinuation over a 2-week period).

### Safety
Vigabatrin has a Boxed Warning with regard to permanent vision loss. Vigabatrin can cause permanent bilateral concentric visual field constriction, including tunnel vision that can result in disability. In some cases, vigabatrin also can damage the central retina and may decrease visual acuity. The onset of vision loss from vigabatrin is unpredictable, and can occur within weeks of starting treatment or sooner, or at any time after starting treatment, even after months or years. Symptoms of vision loss from vigabatrin are unlikely to be recognized by patients or caregivers before vision loss is severe. The risk of vision loss increases with increasing dose and cumulative exposure, but there is no dose or exposure known to be free of risk of vision loss. Vision assessment is recommended at baseline (no later than 4 weeks after starting vigabatrin), at least every 3 months during therapy, and about 3 to 6 months after the discontinuation of therapy. Once detected, vision loss due to vigabatrin is not reversible. Risk of new or worsening vision loss continues as long as vigabatrin is used. Because of the risk of vision loss, vigabatrin should be withdrawn from patients with refractory complex partial seizures who fail to show substantial clinical benefit within 3 months of initiation and within 2 to 4 weeks of initiation for patients with infantile spasms, or sooner if treatment failure becomes obvious. Because of the risk of permanent vision loss, vigabatrin is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the Vigabatrin REMS Program. Under the Vigabatrin REMS Program, prescribers must be certified by enrolling in the program, agreeing to counsel patients on the risk of vision loss and the need for periodic monitoring of vision, and reporting any event suggestive of vision loss to Lundbeck. Patients must also enroll in the program, and pharmacies must be certified and must only dispense to patients authorized to receive vigabatrin.

**Guidelines/Recommendations**

In 2012 the American Academy of Neurology (AAN) and the Child Neurology Society updated the evidence-based guideline for the medical treatment of infantile spasms. The guidelines note that low-dose adrenocorticotropic hormone (ACTH) is a first-line agent for the short-term treatment of infantile spasms. ACTH or vigabatrin may be useful for short-term treatment of infantile spasms, with ACTH considered preferentially over vigabatrin. Hormonal therapy (ACTH or prednisolone) may be considered for use in preference to vigabatrin in infants with cryptogenic infantile spasms, to possibly improve developmental outcome. A shorter lag time to treatment of infantile spasms with either hormonal therapy or vigabatrin possibly improves long-term developmental outcomes. The Infantile Spasms Working Group (ISWG) published a US consensus report on infantile spasms in 2010. Data regarding ACTH use and vigabatrin use in infantile spasms were detailed. ACTH is an effective first-line therapy for infantile spasms. Vigabatrin is considered a drug of first choice for infantile spasms comorbid with tuberous sclerosis complex, and it is the drug of second or third choice for children with other symptomatic or cryptogenic infantile spasms.

The American Academy of Neurology (AAN) and the American Epilepsy Society published a guideline update for treatment-resistant epilepsy (2018) that clobazam is probably effective as add-on therapy for LGS and is possibly effective as add-on therapy for treatment-resistant adult focal epilepsy. Vigabatrin is effective as add-on therapy in treatment-resistant adult focal epilepsy based on two Class I studies, but it should not be used as a first-line treatment. The benefits of vigabatrin should be weighed against the risks, particularly the risk of irreversible retinopathy.

**References**
